Prostatitis and Prostate Cancer Development
前列腺炎和前列腺癌的发展
基本信息
- 批准号:8677581
- 负责人:
- 金额:$ 40.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Prostatitis and prostate cancer are extremely common diseases in men, but the relationship between these two diseases is unknown. While acute prostatitis is thought to be infectious in nature, the etiology of chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) and asymptomatic inflammatory prostatitis remains unclear. By studying Aire-deficient mice that have defective immune tolerance and develop spontaneous prostatitis, we have identified a novel prostate autoantigen. Moreover, we have found that CP/CPPS patients with biopsy-proven inflammation in their prostate glands possess immune responses to the analogous human protein, semenogelin (Sg). These results provide new evidence to support autoimmunity as a potential cause for chronic prostatitis. Moreover, by assessing for immune responses to Sg, we may be able to detect prostate inflammation in symptomatic or asymptomatic men. Animal models as well as clinical observations demonstrate that chronic inflammation can enhance the development or certain tumors. We hypothesize that chronic prostatitis contributes to prostate cancer development. The overall objectives of this proposal are to examine: 1) whether there is an association between an immune responses to the prostate autoantigen Sg and prostate cancer in humans; and 2) whether chronic inflammation can enhance the development of prostate cancer in mouse models. In specific aim 1, we will determine whether immune responses to Sg are associated with the presence of inflammation and/or prostate cancer in men undergoing prostate biopsy. In the specific aim 2, we will determine whether chronic prostatitis can alter the development of tumors in mouse models of prostate cancer. This proposal will provide insight in the role of chronic inflammation and prostate cancer development. Moreover, these results could provide a rationale for prostate cancer prevention by treating chronic prostatitis.
描述(由申请人提供):前列腺炎和前列腺癌是男性极为常见的疾病,但是这两种疾病之间的关系尚不清楚。虽然急性前列腺炎本质上是传染性的,但慢性前列腺炎和慢性骨盆疼痛综合征(CP/CPPS)的病因尚不清楚。通过研究缺乏免疫耐受性并发展自发前列腺炎的AIRE缺陷小鼠,我们已经确定了一种新型的前列腺自身抗原。此外,我们发现,前列腺腺体炎症的CP/CPP患者对类似的人蛋白塞木凝素(SG)具有免疫反应。这些结果为支持自身免疫性作为慢性前列腺炎的潜在原因提供了新的证据。此外,通过评估对SG的免疫反应,我们可能能够检测到有症状或无症状男性的前列腺炎症。动物模型以及临床观察结果表明,慢性炎症可以增强发育或某些肿瘤。我们假设慢性前列腺炎有助于前列腺癌的发展。该提案的总体目标是检查:1)对人类对前列腺自身抗原SG的免疫反应与人类前列腺癌之间是否存在关联; 2)慢性炎症是否可以增强小鼠模型中前列腺癌的发展。在特定目标1中,我们将确定对SG的免疫反应是否与接受前列腺活检的男性中的炎症和/或前列腺癌有关。在特定目标2中,我们将确定慢性前列腺炎是否可以改变前列腺癌小鼠模型中肿瘤的发展。该提案将为慢性炎症和前列腺癌发展的作用提供洞察力。此外,这些结果可以通过治疗慢性前列腺炎来为预防前列腺癌的理由提供理由。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Lawrence Fong的其他基金
Determinants of response to cancer immunotherapy
癌症免疫治疗反应的决定因素
- 批准号:1045803010458030
- 财政年份:2021
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
Determinants of response to cancer immunotherapy
癌症免疫治疗反应的决定因素
- 批准号:1029996810299968
- 财政年份:2021
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
Determinants of response to cancer immunotherapy
癌症免疫治疗反应的决定因素
- 批准号:1066491810664918
- 财政年份:2021
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
前列腺癌免疫治疗反应的分子和免疫驱动因素
- 批准号:1047795010477950
- 财政年份:2018
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
Determinants of prostate cancer sensitivity to PD-1 blockade
前列腺癌对 PD-1 阻断敏感性的决定因素
- 批准号:98491299849129
- 财政年份:2018
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
前列腺癌免疫治疗反应的分子和免疫驱动因素
- 批准号:1022479710224797
- 财政年份:2018
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
前列腺癌免疫治疗反应的分子和免疫驱动因素
- 批准号:97883219788321
- 财政年份:2018
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
Immunotherapy of human bladder cancer
人类膀胱癌的免疫治疗
- 批准号:96549839654983
- 财政年份:2015
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
Immunotherapy of human bladder cancer
人类膀胱癌的免疫治疗
- 批准号:91041299104129
- 财政年份:2015
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
Immunotherapy of human bladder cancer
人类膀胱癌的免疫治疗
- 批准号:89654568965456
- 财政年份:2015
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
相似国自然基金
剪接因子SNRPA1通过调节R-loop稳态影响肺腺癌发展进程的机制研究
- 批准号:32360143
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
TGS1调控DNA损伤修复影响三阴性乳腺癌放疗敏感性的机制研究
- 批准号:82303696
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
遗传变异调控可变多聚腺苷酸化影响胰腺癌风险的分子流行病学研究
- 批准号:82373663
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
AUTS2通过表观遗传调控BRN2转录活性影响肿瘤微环境促进治疗相关神经内分泌前列腺癌发生的研究
- 批准号:82303905
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
FAD合成酶通过调控线粒体氧化磷酸化影响三阴性乳腺癌细胞衰老的作用及机制研究
- 批准号:82303048
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
WASHINGTON UNIVERSITY HUMAN TUMOR ATLAS RESEARCH CENTER
华盛顿大学人类肿瘤阿特拉斯研究中心
- 批准号:1081992710819927
- 财政年份:2023
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
Full Project 1: Defining Mechanisms of MICAL-dependent Pancreatic Cancer Cell Migration
完整项目 1:MICAL 依赖性胰腺癌细胞迁移的定义机制
- 批准号:1076227310762273
- 财政年份:2023
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
Interactions Between the Microbiota and Helicobacter pylori in Gastric Carcinogenesis
微生物群与幽门螺杆菌在胃癌发生中的相互作用
- 批准号:1070913510709135
- 财政年份:2023
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
The Role of Uterine Glycogen in Establishing a Successful Pregnancy
子宫糖原在成功怀孕中的作用
- 批准号:1072589410725894
- 财政年份:2023
- 资助金额:$ 40.16万$ 40.16万
- 项目类别:
United for Health Equity - Living PDX Program (U4HELPP)
United for Health Equity - Living PDX 计划 (U4HELPP)
- 批准号:1073331010733310
- 财政年份:2023
- 资助金额:$ 40.16万$ 40.16万
- 项目类别: